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Selective serotonin reuptake inhibitors (SSRIs) are commonly recognized as the
pharmacological treatment of choice for patients with depressive disorders, yet their use
in adolescent populations has come under scrutiny following reports of minimal efficacy
and an increased risk of suicidal ideation and behavior in this age group. The biological
mechanisms underlying these effects are largely unknown. Accordingly, the current study
examined changes in hippocampal protein expression following chronic administration of
paroxetine in drinking water (target dose = 10mg/kg for 22 days) to adult and adolescent
rats. Results indicated age-specific changes in protein expression, with paroxetine
significantly altering expression of 8 proteins in adolescents only and 10 proteins solely
in adults. A further 12 proteins were significantly altered in both adolescents and adults. In
adults, protein changes were generally suggestive of a neurotrophic and neuroprotective
effect of paroxetine, with significant downregulation of apoptotic proteins Galectin 7 and
Cathepsin B, and upregulation of the neurotrophic factor Neurogenin 1 and the antioxidant
proteins Aldose reductase and Carbonyl reductase 3. Phosphodiesterase 10A, a signaling
protein associated with major depressive disorder, was also downregulated (−6.5-fold)
in adult rats. Adolescent rats failed to show the neurotrophic and neuroprotective
effects observed in adults, instead displaying upregulation of the proapoptotic protein
BH3-interacting domain death agonist (4.3-fold). Adolescent protein expression profiles
also suggested impaired phosphoinositide signaling (Protein kinase C: −3.1-fold) and
altered neurotransmitter transport and release (Syntaxin 7: 5.7-fold; Dynamin 1: −6.9-fold).
The results of the present study provide clues as to possible mechanisms underlying the
atypical response of human adolescents to paroxetine treatment.
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INTRODUCTION
Selective serotonin reuptake inhibitors (SSRIs) are commonly rec-
ognized as the pharmacological treatment of choice for patients
with depressive disorders, and have dominated the antidepressant
market since the late 1990s (Mant et al., 2004). SSRIs are gener-
ally preferred over the older tricyclic antidepressants (TCAs) and
monoamine oxidase inhibitors (MAOIs) due to their more favor-
able side-effect profile, ease of use, relative safety in overdose,
and comparable efficacy (Fava and Kendler, 2000). However,
the safety and efficacy of SSRIs for the treatment of adolescent
depression is a topic of considerable debate. Various studies have
suggested that SSRIs, with the possible exception of fluoxetine
(Whittington et al., 2004), have minimal efficacy in young peo-
ple (Cheung et al., 2005; Tsapakis et al., 2008) and are associated
with increased risk of psychiatric adverse effects including sui-
cidal ideation and behavior (Hammad et al., 2006; Stone et al.,
2009). Nevertheless, the association between SSRIs and suicidality
remains uncertain, with population studies suggesting a negative
relationship between SSRI use and youth suicide (Gibbons et al.,
2007). In addition, the neural mechanisms underlying these age-
specific effects are unknown.
SSRIs act by selectively binding to and inhibiting the sero-
tonin transporter (SERT), which is responsible for the reuptake of
synaptic serotonin (5-hydroxytryptamine; 5-HT) (Frazer, 1997).
While this inhibition of reuptake leads to an acute increase in
synaptic 5-HT (Bosker et al., 1995) SSRIs generally take 2–4 weeks
to reach full efficacy (Delago, 2004), thus other mechanisms
appear to be involved in their antidepressant actions. Various neu-
roadaptations correlate with the onset of antidepressant efficacy,
including desensitization and/or downregulation of 5-HT1A, 5-
HT1B and 5-HT2C receptors (Artigas et al., 2001; Yamauchi et al.,
2004); upregulation of dopaminergic tone (Di Giovanni et al.,
2008); increases in neurogenesis (Feldmann et al., 2007); and
stimulation of key transcription factors such as cAMP-response
element binding protein (CREB) and trophic factors such as
brain-derived neurotrophic factor (BDNF) (Hyman, 2006).
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However, it is not clear whether these neural effects also occur
in the developing brain. Adolescence is a critical developmental
period characterized by high levels of neuroplasticity and neural
reorganization. These processes could conceivably be disrupted
by antidepressantmedications, producing atypical behavioral and
emotional effects. This hypothesis was explored in the current
study through the use of an adolescent animal model. The ado-
lescent period in male rats spans from approximately post-natal
day (PND) 28 until PND 55 (Spear, 2007). During this period
rats display adolescent-typical behavioral and neural characteris-
tics including elevated risk-taking and social interaction (Crews
et al., 2007); increased myelination, synaptic pruning and neu-
rogenesis (Paus, 2005; Hodes et al., 2009); general upregulation
of serotonergic tone (Murrin et al., 2007); and heightened phys-
iological responses to stress (McCormick and Mathews, 2010).
Interestingly, adolescent rodents show a behavioral response to
SSRIs that tends to reflect the atypical reaction in adolescent
clinical populations. Peri-pubertal mice treated with fluoxetine
display a paradoxical anxiogenic response (Oh et al., 2009) and
fail to increase struggle on the forced swim test (FST) (Mason
et al., 2009), suggesting limited efficacy in juvenile populations.
We have previously reported similar behavioral findings in ado-
lescent rats treated with paroxetine (PRX), and further demon-
strated that these atypical behavioral responses are accompanied
by opposite serotonergic and dopaminergic neuroadaptations to
those observed in adult rats (Karanges et al., 2011).
Located in the medial temporal lobe, the hippocampus con-
nects to the amygdala and prefrontal cortex, regions involved
in control of emotion and cognition respectively, and also plays
a role in regulation of hypothalamic-pituitary-adrenal (HPA)
axis function (Duman and Monteggia, 2006). Furthermore, the
hippocampus appears particularly susceptible to stress-induced
morphological changes (McEwen, 2001). Hippocampal atrophy
has been observed in patients with major depressive disorder
(MDD) and animal models of chronic stress, with these effects
often reversed by antidepressant treatment (McKernan et al.,
2009). Thus, the hippocampus represents a key site for depres-
sogenic neural changes and corresponding restorative antidepres-
sant action.
In order to further explore developmental differences in the
antidepressant response, and to reveal potential mechanisms
underlying the atypical response in adolescents, the present study
investigated differential changes in hippocampal protein expres-




The subjects were 32 adolescent (PD 28; 77–118 g) and 32 adult
(PD 70; 313–447 g) experimentally naïve male albino Wistar rats
(Animal Resource Centre, Perth, Australia), housed in age- and
treatment-matched groups (adults: 4/cage; adolescents: 8/cage)
with food and water freely available at all times. Home cages
were kept in a temperature- (22 ± 2◦C) and humidity-controlled
colony room with 12-h reverse light cycle (lights on at 21:00 h).
Care was taken to minimize the number of animals used and their
suffering. All experimentation was approved by the University
of Sydney Animal Ethics Committee in accordance with the
Australian Code of Practice for the Care and Use of Animals for
Scientific Purposes.
DRUG TREATMENT AND EXPERIMENTAL DESIGN
Rats were randomly divided into four groups (n = 16):
Adult/PRX, Adult/Control, Adolescent/PRX and
Adolescent/Control, such that half of each developmental
cohort received PRX solution in place of standard drinking
water. Administration via drinking water has previously been
successfully employed in our laboratory (Thompson et al., 2004)
and was chosen due to the short half-life of PRX (Owens et al.,
2000). Paroxetine hydrochloride was obtained from Sequoia
Research Biochemicals (Pangbourne, UK) and administered at
a target dose of 10mg/kg. The dose was selected on the basis of
previous literature showing antidepressant and neurochemical
effects of this dose in adult rats (Carlson et al., 1996; Sillaber et al.,
2008), and to approximate therapeutic plasma concentrations in
humans (DeVane, 1999). Prior to target dose administration, a
5mg/kg half-dose was administered for 3 days in accordance with
recommendations for the treatment of children and adolescents
with SSRIs (Fleming, 2007). Taking body weight and fluid intake
into account, PRX was dissolved in water at the appropriate
concentration, adjusted continuously, and administered for 22
days in light-proof bottles in place of standard drinking water.
The concentrations of PRX present in plasma at the end of this 22
day period have been previously reported (Karanges et al., 2011).
Although both adolescents and adults exhibit concentrations well
within the therapeutic range (10–600 ng/ml; DeVane, 1999), they
were significantly lower in adolescents (105.19 ± 17.49 nmol/l)
than in adults (308.59 ± 80.52 nmol/l) (p < 0.05).
EUTHANASIA AND SAMPLE COLLECTION
On day 22 of drug administration, rats were euthanized by
decapitation. Brains were rapidly removed and the hippocampus
manually dissected out over ice and snap-frozen in liquid nitro-
gen. Samples were stored at −80◦C until required for proteomic
analysis.
TWO-DIMENSIONAL GEL ELECTROPHORESIS (2DE) PROTEOMIC
ANALYSIS
The hippocampi of 24 rats (n = 6/group) were used for pro-
teomic analysis. Protein extraction and analysis was performed
as previously described (Ahmed et al., 2012; Kashem et al., 2012),
using a protocol optimized for cytosolic proteins. Hippocampal
tissue was homogenized in buffer consisting of 7M urea, 2M
thiourea, 1% C7bZO and 40mMTris, sonicated and pelleted. The
supernatant was reduced and alkylated in 5mM tributylphos-
phine (TBP) and 10mM acrylamide monomer and quenched
using 10mM dithiothreitol (DTT). The mixture was acidified
(pH approximately 6.0) with citric acid and precipitated by ace-
tone. The precipitant was pelleted, air-dried and resuspended in
7M urea, 2M thiourea and 1% C7bZO.
Protein concentration was determined by the Bradford
method (Bradford, 1976). Immobilized pH gradient strips (IPG
strips; 11 cm, pH 4–7) were rehydrated with samples containing
400μg protein for 6 h at room temperature. Re-hydrated strips
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were focused using the ElectrophyoretIQ3 system (Proteome
Systems Ltd, Australia) for a total of 120 kVh. IPG strips
were equilibrated using ProteomIQ™ SDS equilibration buffer
and loaded onto SDS-PAGE gels (8–16%, 10 × 15 cm) for
second dimension separation by the ElectrophoretIQ3 system
(30mA/gel, 25◦C for 110min; Proteome Systems, Australia). Gels
were fixed with methanol [25% (v/v)] and acetic acid [10% (v/v)]
and stained using colloidal Coomassie Blue for spot visualization.
A total of 48 gels were prepared (n = 6/group, in duplicate).
Gels were digitized at 400 dots per inch using a transmis-
sive flatbed scanner (UMAX) and analysed using Phoretix 2D
Expression software (Non-linear Dynamics Ltd., UK). To assist
with comparison and reduce within group variation, averaged
gels were created using the 12 gels for each group, with averaging
parameters set at 70% (i.e., for a spot to appear in the averaged
gel, it must occur in 70% of all gels in the group). Normalized
spot volumes were calculated as the natural log of spot pixel value,
allowing for calibration of data between different sample runs
and correction for experimental variation. Fold changes in pro-
tein expression were calculated as the ratio of the normalized
spot volume for the treatment group and age-matched control.
Independent-samples t-tests (p < 0.05) were performed using
the normalized volume of spots from age-matched Control and
Paroxetine-treated groups.
Protein spots identified as significantly altered were destained
in 50mM ammonium bicarbonate and acetonitrile (ACN) solu-
tion (60:40) for 1 h at room temperature. Spots were dried and
rehydrated in a tryptic digest solution (12 ng/μl porcine sequenc-
ing grade trypsin [Promega, USA] in 50mM NH4HCO3) at 4◦C
for 1 h. Residual digest solution was removed and the gel pieces
suspended in 50mM NH4HCO3for 3 h at 37◦C. The peptide
mixtures were purified using C18 Perfect Pure Tips (Eppendorf,
Germany), and the sample eluted onto a MALDI sample plate
with 2μl matrix solution [5mg/ml solution of α-cyano-4-
hydroxy-cinnamic acid (Sigma-Aldrich, USA) in 70% ACN/0.1%
v/v trifluoroacetic acid (TEA)] and allowed to air dry. Samples
were analysed bymatrix assisted laser desorption/ionisation time-
of-flight mass spectrometry (MALDI-TOF MS) using an Applied
Biosystems Voyager with MALDI source (Sydney University
Proteome Research Unit, SUPRU). The mass fingerprint data
(MALDI spectra) were searched against the Swiss-Prot database
using the MASCOT search engine (http://www.matrixscience.
com). The probability-based MOWSE (molecular weight search)
algorithm was used to determine protein identities from peptide
fragment masses (Pappin et al., 1993). Positive protein identifica-
tions were based on a significant MOWSE score (>54% peptide
match, Rattus database), in conjunction with matched pI and
molecular weight values as estimated from 2D gels.
RESULTS
The averaged gels for Adult/PRX, Adult/Control, Adolescent/PRX
and Adolescent/Control displayed 550, 563, 557, and 540 spots
respectively. Thirty-one protein spots were differentially regu-
lated in adolescent and 45 in adult PRX-treated rats (p < 0.05),
with 14 of these spots significantly altered by PRX in both
adults and adolescents. In adolescents, 11 spots were increased
more than 2-fold, and 10 were decreased more than 2-fold. In
adults, these values were 8 and 21 respectively. These differ-
entially expressed spots were identified as 30 different proteins
using MALDI-TOF MS, with 8 proteins significantly altered in
adolescents only, 10 proteins in adults only, and 12 proteins
altered in both age groups. A list of proteins differentially reg-
ulated by PRX in adult and adolescent rats, and those changed
in both cohorts, is shown in Table 1. Figure 1A shows a repre-
sentative 2-DE gel image of protein expression in the hippocam-
pus of an Adult/Control rat. Magnified images of protein spots
23124 (Protein kinase C), 23664 (Tryptophan-5-hydroxylase 1)
and 23204 (BH3-interacting domain death agonist) and normal-
ized spot volumes from each of the 4 groups are also shown
(Figures 1B,C respectively).
DISCUSSION
Use of antidepressants for the treatment of depressive disorders
in adolescents is widespread, yet the impact of these drugs on
the developing brain is still unclear. The present study investi-
gated proteomic changes in the hippocampus of adolescent and
adult rats treated chronically with the SSRI PRX. Differential
changes in protein expression in adolescents compared to adults
may provide clues as to why the adolescent brain responds dif-
ferently to antidepressants, both in terms of reduced efficacy and
increased risk of psychiatric side effects such as suicidal ideation.
We have previously reported that adolescent rats treated with PRX
as described in the current study fail to show an antidepressant-
like behavioral pattern on the FST. In addition, adolescent rats
treated with PRX show a significant reduction in social behavior
and appear more susceptible than adults to increased anxiety in
the early stages of SSRI treatment (Karanges et al., 2011). This
elevation in adverse effects in adolescents is present despite sub-
stantially lower, although still therapeutically relevant (DeVane,
1999) plasma PRX in adolescents compared to adults.
Although several previous studies have investigated proteomic
changes in adult rodents or neural cell cultures following the
administration of PRX and other SSRIs (e.g., McHugh et al.,
2008, 2010; Sillaber et al., 2008), this is the first study to our
knowledge that has examined changes occurring in the adoles-
cent brain. We provide evidence that chronic PRX treatment
produces differential, although overlapping, changes in the hip-
pocampal proteome in adolescent rats compared to adults, and
these changes can be linked to the regulation of neurotrans-
mitter function, major signaling pathways, cell proliferation and
death, oxidative stress, and cytoskeleton structure. Figure 2 is a
schematic proposing an overview of the major protein changes,
their potential interactions and functional significance.
CHANGES IN PROTEINS INVOLVED IN REGULATION OF
NEUROTRANSMISSION
Tryptophan 5-hydroxylase 1 (TPH1) is the rate-limiting enzyme
in 5-HT biosynthesis and alterations in this enzyme have been
implicated in depression (Gizatullin et al., 2006), suicide attempts
(Galfalvy et al., 2009), deliberate self-harm (Pooley et al., 2003)
and the antidepressant-treatment response (Ham et al., 2007).
The upregulation of TPH1 (>4-fold) in adults may in part under-
lie the positive treatment response in PRX-treated adults and
the more equivocal therapeutic response in adolescents. Indeed,
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Table 1 | Differentially expressed proteins in the hippocampus of adult and adolescent paroxetine- (PRX) treated rats (n = 6/group).




Changed in adults and adolescents
23655 Phosphodiesterase 4A (PDE4A) P54748 5.37 41 5 21 2.57* 2.80*
23112 Protein kinase A (PKA) Q5BJR2 5.10 24 5 17 2.23* 2.20*
23387 Protein phosphatase 6, catalytic
subunit (PP6c)
Q64620 5.64 35 4 16 −0.70* −2.26*
23091 Guanine nucleotide-binding
protein Gi, α1 subunit (Gnai1)
P10824 5.66 35 6 31 2.11* 2.38*
23717 14-3-3 protein epsilon (14-3-3-ε) P62259 4.63 29 5 22 1.51* 1.53*
Changed in adults only
22951 Phosphodiesterase 10A (PDE10A) Q9QYJ6 6.65 74 12 24 −6.48* −1.44
23450 Rab28 Q6IN03 5.30 24 4 25 −1.80* 1.00
Changed in adolescents only
23124 Protein kinase C (PKC) Q568X9 6.01 33 10 19 −1.03 −3.12*
OXIDATIVE STRESS PROTEINS
Changed in adults only
23660 Carbonyl reductase 3 (CBR3) Q9JJN7 5.59 30 7 26 3.51* 1.33
23093 Aldose reductase (AR) P07943 6.28 35 5 31 3.09* 1.44
APOPTOTIC PROTEINS
Changed in adults only
23381 Galectin-7 (GAL7) P97590 6.43 15 5 29 −3.81* ND
23246 Cathepsin B (CTSB) P00787 5.14 27 4 18 −1.58* −1.28
Changed in adolescents only
23204 BH3-interacting domain death
agonist (BID)
Q9JLT6 4.82 22 4 37 ND 4.34*
METABOLIC PROTEINS
Changed in adults and adolescents
23538 Cytochrome P450 1B1 (CYP1B1) Q9ESW3 5.58 25 6 34 −4.50* −4.08*
23560 Tyrosine aminotransferase (TAT) P04694 5.13 50 6 14 2.17* 2.22*
23251 Ferritin light chain 1 (FTL1) P02793 5.88 20 5 33 2.23* 2.20*
23105 Guanosine monophosphate
reductase 2 (GMPR2)
Q5FVP6 6.51 31 5 24 −2.32* −2.19*
23612 5-Hydroxytryptamine receptor 3B
(5-HT-3B)
Q9JJ16 5.34 50 6 24 1.89* 1.55*
23664 Tryptophan-5-hydroxylase 1
(TPH1)
P09810 6.30 51 6 15 4.32* 1.55*
Changed in adults only




P10937 4.94 21 4 21 −4.10* 1.40
23396 Choline-phosphate
cytidylyltransferase A (CCTa)
P19836 6.58 41 8 25 −2.10* 1.40
23150 Quinone reductase 2 (QR2) Q6AY80 6.90 26 6 27 −1.85* −1.17
Changed in adolescents only
23464 Interferon γ inducible protein 30 Q499T2 4.77 27 5 31 ND 3.85*
23249 Phospholipase C (δ-1) (PLCδ1) P10688 5.36 27 7 31 −1.13 −1.63*
CYTOSKELETAL PROTEINS
Changed in adults and adolescents
23237 Dynamin-1 (DYN1) P21575 6.97 22 4 22 −2.63* −6.89*
(Continued)
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Table 1 | Continued
Spot number Protein name Accession pI MW Matched Sequence Fold change
number Cover (%)
Adult Adolescent
Changed in adolescents only
23223 Tropomyosin-4 (TM4) P09495 4.66 28 4 18 −1.23 −2.25*
23437 Pannexin-1 (PX1) P60570 6.34 40 6 20 −1.00 −1.79*
CALCIUM-REGULATING PROTEINS
Changed in adolescents only
23104 Syntaxin 7 (STX7) O70257 6.02 29 5 23 ND 5.74*
23720 Calcium binding protein 1 (CBP1) O88751 4.77 25 6 31 1.42 1.53*
Significant alterations in protein expression in the hippocampus of adolescent and adult PRX-treated rats were established by comparison with age-matched VEH-
treated averaged gels. Protein spots of interest were excised and subjected to MALDI-TOF MS. Positive protein identifications were based on a significant MOWSE
score (>54%), with matched pI and Mw values.
pI, isoelectric point; MW, molecular weight; ND, not detectable.
*p < 0.05, Paroxetine vs. age-matched Control.
reduced expression of TPH1 has been associated with poorer
response to PRX in other animal studies (Nakamura et al., 2006).
Only adult rats given PRX showed a significant decrease in
phenylethanolamine N-methyltransferase (PNMT), an impor-
tant enzyme in catecholamine biosynthesis and in the conversion
of noradrenaline to adrenaline. PNMT transcription and activ-
ity is primarily regulated by glucocorticoids, with transcription
increased in response to both chronic and acute stress (Sabban
et al., 1995; Spasojevic et al., 2010). In addition, hypophysec-
tomised animals, showing reduced corticosterone concentrations,
show reductions in PNMTmRNA and activity (Jiang et al., 1989),
suggesting that the reduction in PNMT expression shown here
in adults may stem from the effects of PRX on the HPA axis.
Indeed, reductions in HPA axis activity is a common response to
antidepressant treatment, probably mediated by increases in glu-
cocorticoid receptor (GR) expression and enhanced GR-mediated
feedback inhibition (Pariante and Lightman, 2008), which may
reduce PNMT expression. PNMT was unchanged here in adoles-
cent rats treated with PRX, supporting the questionable efficacy
of this drug on the developing brain.
Syntaxin 7 was upregulated almost 6-fold in PRX-treated ado-
lescents but was below the detectable limit in adults. Syntaxin 7 is
a transmembrane protein that forms a component of an endoso-
mal SNARE complex, playing a role in the transport of vesicles
containing neurotransmitters (Antonin et al., 2002; Rizo et al.,
2006). PRX binds to and blocks SERT, preventing 5-HT reuptake,
and thus potentially changes the rate of vesicular packaging and
release of 5-HT.
CHANGES IN PROTEINS LINKED TOMAJOR SIGNALLING PATHWAYS
Expression of the signaling protein, protein kinase A (PKA), was
increased (∼2-fold) in both adolescents and adults treated with
PRX. PKA is a serine/threonine kinase that plays an important
role in the adenylate cyclase-cyclic adenosine monophosphate
(cAMP) signaling system (Gould and Manji, 2002). PKA is acti-
vated in response to extracellular signals such as the binding of
neurotransmitters to their receptors (Paez-Pereda, 2005). Once
activated, PKA is involved in the phosphorylation and regulation
of various cellular components including transcription factors,
cytoskeletal proteins, ion channels and downstream signaling
proteins and thereby plays a role in the regulation of cell survival,
neurotransmitter production and release, receptor function and
synaptic plasticity (Gould and Manji, 2002; Dwivedi and Pandey,
2011).
PKA may play an important role in depression and the ther-
apeutic effects of antidepressants. Decreased PKA activity has
been associated with suicide in both adult and adolescent popula-
tions (Dwivedi et al., 2004b; Pandey et al., 2005) and is observed
in animal models of sub-chronic and chronic stress (Dwivedi
et al., 2004a; Dwivedi and Pandey, 2011). In addition, long-
term administration of PRX and other antidepressants modifies
the distribution, cAMP-binding capabilities and activity of PKA
(Popoli et al., 2001). Therapeutic effects arising from changes in
PKA may be mediated by the downstream phosphorylation and
activation of CREB, and subsequent transcription of BDNF, both
of which have been associated with depression and the antide-
pressant response (Chen et al., 2001; Khundakar and Zetterström,
2006; Dwivedi and Pandey, 2011).
Upregulation of the inhibitory guanine nucleotide-binding
protein (Gnai; Gi) in both age groups indicates a further mod-
ification of signaling pathways by PRX. Neurotransmitters and
their receptors are linked to downstream signaling pathways such
as the adenylate cyclase system via multi-subunit G proteins
(Avissar and Schreiber, 2006). The various G protein subunits
have different effects on downstream signaling, with adenylate
cyclase activity stimulated by Gs and inhibited by Gi (Gould and
Manji, 2002). Antidepressants are thought to produce changes
in the activity and/or expression of both Gs and Gi subunits
(Avissar and Schreiber, 2006), and have been reported to nor-
malize reduced Gi levels in patients with depression (Avissar and
Schreiber, 1994).
The purine nucleotides cAMP and cGMP are vital compo-
nents in neuronal signaling pathways and tight regulation of
these second messengers is required for maintenance of signal-
ing integrity. Guanosine monophosphate reductase 2 (GMPR2)
is involved in the recycling of adenosine and guanine nucleotides
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FIGURE 1 | Continued
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FIGURE 1 | Results of proteomics conducted on the hippocampus of
adult and adolescent rats chronically treated with paroxetine
(10mg/kg). (A) A representative 2-DE gel image of a hippocampal
protein sample from an Adolescent/Control rat. Approximately 400μg of
protein was loaded onto an IPG strip (pH 4–7) followed by 2-dimensional
electrophoresis. Experimental masses are located on the Y-axis and pI’s
on the X-axis. Spot numbers are given in Table 1. (B) Cropped 2-DE gel
images of 3 hippocampal protein spots from each of the 4 experimental
groups: Adult/PRX, Adult/Control, Adolescent/PRX and Adolescent/Control.
PRX downregulated Protein kinase C (PKC; spot 23124; top panel) and
upregulated BH3-interacting domain death agonist (BID; spot 23204;
bottom panel) in adolescents only. Tryptophan-5-hydroxylase 1 (TPH1;
spot 23664; middle panel) was upregulated in 4.3-fold adult rats, but only
1.6-fold in adolescents. (C) Normalized volumes of Protein kinase C,
Tryptophan-5-hydroxylase and BH3-interacting domain death agonist.
∗p < 0.05.
(Zhang et al., 2003) and phosphodiesterases (PDEs) are responsi-
ble for their degradation (Reierson et al., 2009). We demonstrate
here PRX-induced modification in protein levels of GMPR2
and two PDEs, PDE10A (cAMP and cAMP-inhibited cGMP
3′,5′-cyclic phosphodiesterase 10A) and PDE4A (cAMP-specific
3′,5′-cyclic phosphodiesterase 4A). PDE4A, which was upreg-
ulated in both adults and adolescents treated with PRX, is
specific for the degradation of cAMP (Reierson et al., 2009).
Increased expression of PDE4A has been previously reported with
a variety of antidepressant treatments (Takahashi et al., 1999;
Esposito et al., 2009), and may be a homeostatic response to
general upregulation of the cAMP signaling pathway (Takahashi
et al., 1999). However, the antidepressant-like actions of the
PDE4 inhibitor rolipram (Li et al., 2009) make it unlikely that
PDE4A upregulation is directly responsible for antidepressant
efficacy.
Downregulation (∼6.5-fold) of PDE10A occurred in adult rats
only. Unlike PDE4, PDE10 subtypes are important in the regula-
tion of both cAMP and cGMP (Reierson et al., 2009) and poly-
morphisms in the gene encoding PDE10A have been associated
with MDD in certain populations (Wong et al., 2006). Chronic
administration of the PDE10A inhibitor papaverine has been
associated with increases in hippocampal CREB, BDNF and trkB
mRNA (Nibuya et al., 1996), suggesting a likely role of PDE10A in
the antidepressant treatment response that is consistent with the
effects of PRX noted here in adults.
Protein kinase C (PKC), a serine/threonine kinase, is a key
component of the phosphoinositide signaling pathway (Gould
and Manji, 2002). PKC is activated following stimulation of var-
ious receptors known to be affected by PRX and other SSRIs,
including 5-HT1A, 5-HT2C and the muscarinic M1 receptor
(Hensler, 2003; Yamauchi et al., 2004; Carrasco and Sandner,
2005). Following activation, PKC phosphorylates downstream
proteins involved in cell proliferation, cell differentiation, apop-
tosis, neurotransmitter release and downregulation of mem-
brane receptor proteins (Nishizuka, 1992; Gould and Manji,
2002). We report here a decrease in PKC in adolescent rats
(>3-fold), with no change apparent in adults. Altered PKC has
been linked to suicide, particularly in adolescent populations
(Pandey et al., 1997, 2004). PKC is also dysregulated in bipo-
lar patients: Increased PKC signaling is observed during acute
manic phases and decreased by chronic treatment with mood
stabilizers (Zarate and Manji, 2009). Interestingly, phospholi-
pase C, also decreased here in adolescents only, is a modera-
tor of PKC activity (Nishizuka, 1992). Decreases in PKC and
the related phosphoinositide signaling pathway may therefore
be linked to the paradoxical response of some adolescents to
antidepressants.
CHANGES IN PROTEINS LINKED TO NEUROGENESIS AND APOPTOSIS
The aforementioned signaling pathways have downstream effects
on cellular processes that influence cell growth and death.
Differential changes in proteins implicated in neurotrophic and
apoptotic pathways in adult and adolescent animals provide many
clues as to the mechanisms underlying the response to PRX in
adolescent humans.
PRX-treated adult rats showed reduced expression of pro-
apoptotic proteins galectin-7 and cathepsin B, and dramati-
cally increased expression (>4-fold) of the neurotrophic protein
neurogenin-1, suggesting a general trophic and anti-apoptotic
effect of PRX in adult animals. Galectin-7 is involved in the induc-
tion of p53-mediated apoptosis (Saussez and Kiss, 2006), while
cathepsin B is a lysosomal cysteine protease implicated in a variety
of apoptotic pathways (Guicciardi et al., 2000; Stoka et al., 2001).
Various other studies have demonstrated anti-apoptotic and neu-
rotrophic effects of antidepressant treatment including upregula-
tion of survival (Murray and Hutson, 2007; Korsten et al., 2008)
and neurotrophic proteins (Chen et al., 2001), and downregula-
tion of pro-apoptotic proteins (Korsten et al., 2008). Indeed, the
neurotrophic actions of antidepressants may be crucial for their
therapeutic effects (Feldmann et al., 2007): Stimulation of neuro-
genesis is a key feature of many antidepressant therapies (Drzyzga
et al., 2009; Malkesman et al., 2009; McKernan et al., 2009) and
suppression of these neurotrophic actions can prevent the relief
of depression-related symptoms (Santarelli et al., 2003).
In contrast to the neurotrophic and anti-apoptotic effects
of PRX in adults, there were no appreciable positive changes
in any of the aforementioned neurotrophic proteins in ado-
lescents. This agrees with studies showing that fluoxetine has
no effect on hippocampal neurogenesis in juvenile and peri-
adolescent rats, despite stimulating neurogenesis in male adults
(Hodes et al., 2009; Oh et al., 2009). In contrast, we observed
dramatic increases (>4-fold) in expression of the pro-apoptotic
protein BH3-interacting domain death agonist (BID) in treated
adolescents. BID, a member of the Bcl-2 family of apoptotic
proteins, acts by sequestering anti-apoptotic proteins such as Bcl-
2 and activating pro-apoptotic family members, Bax and Bak
(McKernan et al., 2009). Interestingly, the pro-apoptotic pro-
tein cathepsin B (decreased in adults) stimulates cleavage of BID,
releasing cytochrome c from the mitochondria and triggering
apoptosis (Stoka et al., 2001). Increases in apoptotic activity
via BID may underlie the increased depression-like behaviors
observed in some human adolescents treated with PRX, especially
considering the recent demonstration of antidepressant effects of
the BID inhibitor, BI-11A7 (Malkesman et al., 2009). Sufferers of
MDD display brain features indicative of elevated apoptosis and
decreased neurogenesis, such as reduced hippocampal volumes
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FIGURE 2 | Schematic representation of protein expression changes
induced by paroxetine in adult (top panel) and adolescent rats (bottom
panel) showing interactions between proteins and their involvement in
key cellular activities. Interaction between G protein-coupled receptors and
their corresponding ligands leads to activation of downstream signaling
pathways. Within these pathways, protein kinases such as PKA, PKC and
CaMKII phosphorylate and regulate proteins impacting on cell growth and
death, neurotransmission, syntaptic plasticity and receptor function. Arrows
represent positive feedback or activation between protein units, while capped
lines represent negative feedback or inhibition. The magnitude of the protein
expression change induced by is represented by the size and color of the
boxes: larger boxes represent larger fold changes, and downregulation is
indicated with gray shading. Boxes with dashed outlines represent
non-significant protein changes. 5-HIAA, 5-hydroxyindoleacetic acid; 5-HT,
5-hydroxytryptamine; 5HT3B, Serotonin 3B receptor; AR, Aldose reductase;
BDNF, Brain-derived neurotrophic factor; BID, BH3-interacting domain death
agonist; CaMKII, Calcium/calmodulin-dependent protein kinase; CBR3,
Carbonyl reductase 3; CREB, cAMP response element binding protein; CTSB,
Cathepsin B; CYP1B1: Cytochrome P450 1B1; DA, Dopamine; DAT,
Dopamine transporter; DYN1, Dynamin 1; GAL7, Galectin 7; GILT, Interferon γ
inducible protein 30; GMPR2, Guanosine monophosphate reductase 2;
GNAI1, Guanine nucleotide-binding protein Gi, α1 subunit; NA, Noradrenaline;
NG1, Neurogenin 1; PDE10A, Phosphodiesterase 10A; PDE4A,
Phosphodiesterase 4A; PKA, Protein kinase A; PKC, Protein kinase C; PLC,
Phospholipase C; PNMT, Phenylethanolamine-N-methyltransferase; PP6c,
Protein phosphatase 6, catalytic subunit; SERT, Serotonin transporter; STX7,
Syntaxin 7; TAT, Tyrosine aminotransferase; TM4, Tropomyosin 4; TPH1,
Tryptophan hydroxylase 1.
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and downregulation of pro-survival proteins and neurotrophins
(Drzyzga et al., 2009; McKernan et al., 2009). Furthermore,
chronic stress, a risk factor for depression, can produce similar
changes, suggesting that these effects may be causal in producing
depression (McKernan et al., 2009).
CHANGES IN ANTIOXIDANT PROTEINS AND PROTEINS LINKED TO
OXIDATIVE STRESS
Antioxidant enzymes play a vital role in the protection of cells
from oxidative stress. Production of oxidizing species is a nor-
mal consequence of a cell’s metabolic processes, yet at high levels
these species can damage intracellular components such as DNA,
proteins and lipids (Ellis, 2007), disrupting signaling pathways
and rendering the cell susceptible to apoptotic or necrotic cell
death (Halliwell, 2001). The central nervous system is particularly
susceptible to oxidative stress due to its high metabolic rate and
unsaturated lipid content, and lower concentration of antioxidant
enzymes compared to other tissues (Maser, 2006).
PRX-treated adults, but not adolescents, showed an upregula-
tion (∼ 3-fold) of two antioxidant enzymes, carbonyl reductase 3
(CBR3) and aldose reductase (AR), suggesting a possible neuro-
protective effect of PRX on the adult but not the developing brain.
CBR3, a member of the short chain dehydrogenase/reductase
(SDR) family, catalyses the reduction of reactive aldehydes gen-
erated through lipid peroxidation (Maser, 2006). Lipid peroxi-
dation and production of reactive oxygen species is elevated in
patients with depression and in animal models of chronic stress
(Bilici et al., 2001; Fontella et al., 2005), and many antidepres-
sants appear to normalize antioxidant activity and markers of
oxidative stress (Bilici et al., 2001; Zafir et al., 2009). Upregulation
of CBR and/or AR likely have similar protective effects. Indeed,
overexpression of a related CBR enzyme known as Sniffer in
Drosophila melanogaster protects neurons against the effects of
hyperoxia-induced oxidative stress (Botella et al., 2004). Similarly,
overexpression of AR and related enzymes decreases the sus-
ceptibility of cells to apoptosis induced by oxidative stress by
stimulating the reduction of reactive aldehydes (Ellis, 2007).
Three other proteins modified by PRX treatment are also
linked to the production and/or reduction of cellular oxida-
tive stress. Interferon gamma inducible protein 30 (GILT, also
known as IFI30 or IP30) was upregulated almost 4-fold in ado-
lescents, but absent in adults. GILT, a lysosomal thiol reductase,
is associated with immune dysregulation and inflammatory dis-
ease (Satoh et al., 2008). Depression has also been associated
with elevated immune function and secretion of inflammatory
cytokines (Maes et al., 1994), thus GILT induction may be asso-
ciated with the depressogenic effects of antidepressants in some
adolescents. This increase in immune activation in MDD may
be linked to oxidative stress: Immune activation stimulates pro-
duction of reactive oxygen species (Bilici et al., 2001). GILT is
also known to positively regulate expression, activity and stability
of the antioxidant enzyme mitochondrial manganese superoxide
dimutase (SOD2) (Bogunovic et al., 2008), hence GILT upregu-
lation may be a compensatory response to the loss of antioxidant
capabilities described above.
Cytochrome P450 1B1 (CYP1B1) was downregulated approx-
imately 4-fold in both adolescents and adults treated with PRX.
CYPs are phase I metabolising enzymes involved in the deactiva-
tion of endogenous compounds, drugs and environmental toxins
(Miksys and Tyndale, 2002). Specifically, CYP1B1 is implicated in
metabolism of the sterols 17β-estradiol and melatonin (Dutheil
et al., 2008), both of which have neuroprotective roles, scaveng-
ing free radicals and protecting against oxidative stress (Goodman
et al., 1996; Maharaj et al., 2006). Given that CYP1B1 is negatively
regulated by melatonin (Chang et al., 2010), and both PRX and
fluvoxamine increase melatonin levels in the brain (Härtter et al.,
2001), it is conceivable that the downregulation of CYP1B1might
be mediated by effects of PRX on melatonin. Increases in synap-
tic 5-HT also stimulate melatonin production, inhibiting CYP1B1
activity (Nathan et al., 1998).
CHANGES IN CYTOSKELETAL PROTEINS
Dynamin-1 is a neuron-specific GTP-hydrolysing protein
involved in synaptic vesicle endocytosis, neurotransmitter release
and dopamine transporter (DAT) internalization (Mortensen
et al., 2008; Wu et al., 2010). Many antidepressants, including
PRX, are cationic amphiphillic drugs (CADs) that suppress
the GTPase activities of dynamin (Rainey et al., 2010), inhibit-
ing endocytosis and neurotransmitter release (Otomo et al.,
2008). We report a marked decrease (6.89-fold) in dynamin-
1 in PRX-treated adolescents, and a significant, but lesser,
decrease in adults, suggesting that the effects of PRX on
dynamin-1 may be exacerbated in adolescents. Interestingly,
a study with sertraline associates the CAD-like qualities of
the drug with its propensity to produce cellular toxicity in
yeast cells (Rainey et al., 2010). The marked effect of PRX
on dynamin-1 in adolescent rats may in part explain the
increased expression of apoptotic proteins. Interestingly, CADs
are also known to inhibit other phospholipid membrane-
associated proteins such as phospholipases (Rainey et al.,
2010).
LIMITATIONS
2DE proteomic analysis is a powerful technique with the
capacity to reveal potential targets for future research on the
adolescent response to antidepressants. However, certain lim-
itations of this technique must be considered when inter-
preting the current findings. Proteomics is an exploratory
method that may result in false positives and often ben-
efits from additional supportive analyses such as western
blotting and/or PCR, which have not been conducted in
the present study. As such, these findings should be inter-
preted with caution, particularly where fold changes do not
exceed 1.5.
Furthermore, a shortcoming of the current study is the
lower plasma PRX levels in adolescent rats compared to
adults, despite provision of equivalent doses (Karanges et al.,
2011). This caveat should be considered particularly where null
results in adolescents accompany significant protein changes
in adults. However, the presence of adverse behavioral effects
(Karanges et al., 2011) and the heightened protein expression
changes in adolescents (for example, in syntaxin 7, dynamin
1 and BID expression), suggest valid results despite lower
plasma PRX.
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CONCLUSIONS
The present study demonstrates that chronic administration
of PRX to adult and adolescent rats produces age-specific
changes in the hippocampal proteome. Although similar changes
were observed in many proteins in both age-groups, there
were notable differences in the expression profiles of pro-
teins implicated in apoptosis, oxidative stress, cytoskeletal
structure, intracellular signaling and serotonergic and cate-
cholaminergic neurotransmission. These findings, while sugges-
tive rather than conclusive, demonstrate that the developing
brain responds to PRX in a manner distinct from the
adult brain, and provides some clues as to the mecha-
nisms underlying the adolescent response to antidepressant
drugs.
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